BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25694352)

  • 1. Tumor-specific mutations in low-frequency genes affect their functional properties.
    Erdem-Eraslan L; Heijsman D; de Wit M; Kremer A; Sacchetti A; van der Spek PJ; Sillevis Smitt PA; French PJ
    J Neurooncol; 2015 May; 122(3):461-70. PubMed ID: 25694352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
    Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
    Gladitz J; Klink B; Seifert M
    Acta Neuropathol Commun; 2018 Jun; 6(1):49. PubMed ID: 29890994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
    Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
    Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.
    Eisenreich S; Abou-El-Ardat K; Szafranski K; Campos Valenzuela JA; Rump A; Nigro JM; Bjerkvig R; Gerlach EM; Hackmann K; Schröck E; Krex D; Kaderali L; Schackert G; Platzer M; Klink B
    PLoS One; 2013; 8(9):e76623. PubMed ID: 24086756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.
    Chittaranjan S; Chan S; Yang C; Yang KC; Chen V; Moradian A; Firme M; Song J; Go NE; Blough MD; Chan JA; Cairncross JG; Gorski SM; Morin GB; Yip S; Marra MA
    Oncotarget; 2014 Sep; 5(17):7960-79. PubMed ID: 25277207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas.
    Liu Y; Hu H; Zhang C; Wang Z; Li M; Jiang T
    Genes Chromosomes Cancer; 2016 Feb; 55(2):169-76. PubMed ID: 26542540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic landscape of extreme responders with anaplastic oligodendroglioma.
    Holdhoff M; Cairncross GJ; Kollmeyer TM; Zhang M; Zhang P; Mehta MP; Werner-Wasik M; Souhami L; Bahary JP; Kwok Y; Hartford AC; Chakravarti A; Yegnasubramanian S; Vogelstein B; Papadopoulos N; Kinzler K; Jenkins RB; Bettegowda C
    Oncotarget; 2017 May; 8(22):35523-35531. PubMed ID: 28388591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
    Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
    Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
    Bettegowda C; Agrawal N; Jiao Y; Sausen M; Wood LD; Hruban RH; Rodriguez FJ; Cahill DP; McLendon R; Riggins G; Velculescu VE; Oba-Shinjo SM; Marie SK; Vogelstein B; Bigner D; Yan H; Papadopoulos N; Kinzler KW
    Science; 2011 Sep; 333(6048):1453-5. PubMed ID: 21817013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].
    Yao K; Duan Z; Hu Z; Bian Y; Qi X
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):663-7. PubMed ID: 25567591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCF12 is mutated in anaplastic oligodendroglioma.
    Labreche K; Simeonova I; Kamoun A; Gleize V; Chubb D; Letouzé E; Riazalhosseini Y; Dobbins SE; Elarouci N; Ducray F; de Reyniès A; Zelenika D; Wardell CP; Frampton M; Saulnier O; Pastinen T; Hallout S; Figarella-Branger D; Dehais C; Idbaih A; Mokhtari K; Delattre JY; Huillard E; Mark Lathrop G; Sanson M; Houlston RS;
    Nat Commun; 2015 Jun; 6():7207. PubMed ID: 26068201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.
    Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T
    Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of CIC-associated CpG island methylation in oligoastrocytoma.
    Sahm F; Lass U; Herold-Mende C; von Deimling A; Hartmann C; Mueller W
    Neuropathol Appl Neurobiol; 2013 Dec; 39(7):831-6. PubMed ID: 23521081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
    Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
    Baumgarten P; Harter PN; Tönjes M; Capper D; Blank AE; Sahm F; von Deimling A; Kolluru V; Schwamb B; Rabenhorst U; Starzetz T; Kögel D; Rieker RJ; Plate KH; Ohgaki H; Radlwimmer B; Zörnig M; Mittelbronn M
    Neuropathol Appl Neurobiol; 2014 Feb; 40(2):205-16. PubMed ID: 24117486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
    Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.